Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Gene Signature Developed Using Machine Learning for Precise Prediction of Relapse and Survival in Resected Stage I-II Pancreatic Ductal Adenocarcinoma

NCT05441189 is registered in ClinicalTrials.gov with The Fourth Affiliated Hospital of Anhui Medical University as lead sponsor.

NCT NCT05441189
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05441189 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Gene Signature Developed Using Machine Learning for Precise Prediction of Relapse and Survival in Resected Stage I-II Pancreatic Ductal Adenocarcinoma
Lead sponsor
The Fourth Affiliated Hospital of Anhui Medical University
Phase
Observational
Overall status
Completed
Start date
April 19, 2021
Completion date
June 22, 2022
Enrollment
70 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

precise prognostic and predictive signature, stage i-ii pancreatic ductal adenocarcinoma (pdac)